228 related articles for article (PubMed ID: 29880274)
1. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
2. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
3. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
[TBL] [Abstract][Full Text] [Related]
4. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
8. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
9. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
[TBL] [Abstract][Full Text] [Related]
10. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
[TBL] [Abstract][Full Text] [Related]
12. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
13. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
14. Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer.
Joshi SS; Handorf ER; Sienko D; Zibelman M; Uzzo RG; Kutikov A; Horwitz EM; Smaldone MC; Geynisman DM
Eur Urol Oncol; 2020 Feb; 3(1):104-111. PubMed ID: 31326500
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
16. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
17. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
18. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T; Bortlicek Z; Poprach A; Pavlik T; Veskrnova V; Honzirkova M; Zemanova M; Fiala O; Kubackova K; Slaby O; Svoboda M; Vyzula R; Dusek L; Melichar B;
Eur Urol; 2016 Sep; 70(3):469-75. PubMed ID: 26746623
[TBL] [Abstract][Full Text] [Related]
20. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
